NCT02257567 2022-11-14A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaHoffmann-La RochePhase 1/2 Completed331 enrolled 81 charts 1 FDA